Jan 26, 2018
NC State Startup Biomarck Pharmaceuticals launches Phase 2 clinical trial for lung cancer treatment
Durham-based Biomarck Pharmaceuticals, a portfolio company of the North Carolina Biotechnology Center, has launched a Phase 2 clinical trial of a potential therapy for treating advanced non-small cell lung cancer (NSCLC).…
